Study Startup: New Battleground In CRO Differentiation Strategy
Source: Oracle Health Sciences

The drug development process is long, arduous, and costly, driving many sponsors to expand their use of contract research organizations (CROs). This move reflects sponsors’ sharper focus on core competencies as they shift the management and conducting of clinical trials to CROs. Research suggests a 7.4% compound annual growth rate for the CRO market through 2019,1 and a market penetration rate of 72% by 2020.2 Yet, at the same time, there are clues that this hefty market penetration signals a maturing market,3 leading to eventual slowing of revenue growth, possible reduction in the number of CROs, and fewer new customers.
VIEW THE WHITE PAPER!
Log In
Signing up provides unlimited access to:
Free Sign Up

Signing up provides unlimited access to:
- Trend and Leadership Articles
- Case Studies
- Extensive Product Database
- Premium Content
HELLO. PLEASE LOG IN.
X
Not yet a member of Clinical Leader? Register today.
ACCOUNT SIGN UP
X
Please fill in your account details
ACCOUNT SIGN UP
Oracle Health Sciences
This website uses cookies to ensure you get the best experience on our website. Learn more